Darin is a veteran business leader with an excellent track record of success. He has over thirty years of leadership experience in the medical device industry, and Darin has been President and Chief Executive Officer (CEO) of three companies before joining Minerva Surgical.

Most recently, he served as President and CEO of EndoGastric Solutions (EGS), which was recently acquired by Merit Medical. Before joining EGS, Darin spent four years in the women's health space as CEO of DYSIS Medical, and prior to DYSIS, he served as the President and CEO of Cogentix Medical, which was acquired by Laborie in April 2018.

Additionally, Darin was Vice President of Sales for the Bard Medical Division of C.R. Bard, and he spent over twelve years with Boston Scientific as a leader of commercial teams focused on the promotion of urology and gynecology technologies.

Eugene V. Skalnyi, M.D. joined the company in January 2011. Prior to that, Dr. Skalnyi served as Vice President of Medical Affairs for several companies, including Sierra Surgical Technologies, Cytyc Surgical Products (acquired by Hologic, Inc.), Novacept Inc. (acquired by Cytyc Corporation), other. In addition, he served as a Medical Advisor and/or member of Board of Directors for various companies, including Meditrina, Inc., CorRx, Inc., IoGyn, Inc. (acquired by Boston Scientific), and Pulse Therapeutic Technology, Inc. Dr. Skalnyi continues to be academically active by serving on the Editorial Advisory Board for the Journal of Minimally Invasive Gynecology. Dr. Skalnyi received his Medical Degree from Moldova State University of Medicine and Pharmacy “Nicolae Testemitanu” in 1988 and sub-specialized in Advanced Operative Endoscopy in 1990.

Brent joined Minerva in November 2024 and is responsible for building and executing the company’s commercial strategy. Brent brings more than 20 years’ experience and a demonstrated track record in building and leading medical device commercial organizations. Previously, Brent was Chief Commercial Officer at Lumicell where he stood up all commercial operations, achieved multiple CPT codes, and built an initial pipeline 4x the company's goal. Prior to that, he was Senior Vice President of Global Commercial Operations at DYSIS Medical, where he oversaw building the business to new heights. He also spent 15 years at Boston Scientific, where he held multiple commercial positions with increasing responsibilities, including Area Vice President of Boston Scientific’s National Accounts team and Director of Marketing and Commercial Integration, where he oversaw the development of dozens of devices. Earlier in his career, Brent spent seven years at Black and Decker in various sales and marketing positions. He holds a B.S. in marketing from the University of South Florida.

Arleen Felt has over 30 years of experience in the Medical Device industry in both Quality Assurance and Operations. Arleen has vast experience working with large, multi-national corporations as well as smaller, start-up device companies. Prior to joining Minerva Surgical in 2021 Arleen held management positions at ZipLine Medical (acquired by Stryker), EarLens, Arqos Surgical, Sierra Surgical, Cytyc Surgical (Acquired by Hologic), Abbott Labs/Hospira, and LifeScan, a Johnson and Johnson Company. In addition, Arleen served as a QA consultant for Minerva Surgical in 2011 during the early development of the Minerva ES system and also worked closely with IOGYN on the development of the Symphion system prior to the acquisition of the product by Boston Scientific. She holds a B.S. Degree in Applied Mathematics from the University of California, Berkeley, and an M.B.A from Santa Clara University. She is also an ASQ certified Biomedical Quality Auditor.

Joanne Long serves as Vice President, Corporate Controller of Minerva Surgical since February 2021. She brings 10 years of experience in accounting, with a focus on health care and medical technology industry. Prior to joining Minerva Surgical, Joanne was Vice President, Corporate Controller at Carbon Health Technologies. She also held financial leadership positions at two other health care companies including Counsyl, Inc., which was acquired by Myriad Genetics, Inc. Joanne began her career in public accounting, spending 6 years at KPMG, LLP, and earned her B.S. in Accounting from University of Queensland, Australia and is an inactive Certified Public Accountant.

Wendy Bowman serves as our VP, Human Resources; she joined us in 2015 as Director of HR. She brings 20 years of in-house and consulting HR experience in large companies, small emerging companies, and venture capital firms. Most recently, Ms. Bowman has been an HR Consultant with Christine Mathews Consulting advising leadership teams and building out HR strategies for business growth. Previously, she held roles at SurgRx (acquired by Ethicon Endo-Surgery, a Johnson & Johnson company) and Procter & Gamble. She received a B.S. in Business Administration from University of Costa Rica.

Klyde Kanegawa serves as our Vice President of Manufacturing, He joined us in 2011 as Director of Operations. Prior to joining our company, he served as Director of Manufacturing Engineering for three companies including SpineView Inc. from August 2009 to October 2011, SurgRx Inc. (acquired by Ethicon Endo-Surgery) from April 2006 to July 2009, and Novacept Inc. (acquired by Cytyc Corporation) from July 2002 to April 2006. He has also served in various engineering roles at ArthroCare Corporation, Cardiac Pathways Corporation, Guidant Corporation, ReSound Corporation, Life Enhancement Technologies Inc., and Life Support Systems Inc. Mr. Kanegawa holds a B.S. Degree in Mechanical Engineering from University of California at Davis and an M.B.A. from Santa Clara University.

Erik Reese serves as our VP of Sales; he joined us in 2015 as a Regional Director to commercialize the Minerva product. He was instrumental in building the first sales teams and “go to market strategy” for Minerva to become one of the most recognizable products in the endometrial ablation space.

Erik came to Minerva Surgical after serving in several leadership roles to commercialize products at Cytyc Surgical, (acquired by Hologic), SurgRx, (acquired by Ethicon Endo Surgery), DFine, (acquired by Merit Medical), and Neomend (acquired by Bard Davol) that ended each with a successful exit in the market. Erik was a key member of the transition teams in several of these acquisitions where he served in Sales Leadership, Sales Training and Global Marketing positions. Erik graduated from Indiana University of Pennsylvania with a B.S. in Marketing and holds Certificates in Executive Leadership from the University of Chicago, London, UK, and Executive Education at Babson College.

Greg Simbro serves as our Vice President of Finance. He joined the company in August 2021 and brings over 10 years of finance and accounting experience with a focus on companies in the healthcare and medical technology industry. Prior to joining Minerva Surgical, Greg held leadership positions within the accounting functions at both GRAIL and Counsyl, Inc. Greg began his career in public accounting as an auditor with BDO USA, LLP. He is an active Certified Public Accountant and holds a B.B.A. in Finance and Accounting, as well as a Masters in Accounting from the University of Wisconsin-Madison.

Catherine Coste has served as a member of our board of directors since February 2021. Ms. Coste retired from Deloitte and Touche LLP in 2020, where she was a senior partner and served as one of Deloitte’s Life Sciences Industry Executive Leaders. She spent 32 years in both corporate and professional services positions leading global finance, internal audit and operations teams. During her career at Deloitte, Ms. Coste was directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. Ms. Coste also has extensive public company board experience, often attending multiple board committee meetings per month, and currently serves as a director and audit committee chair for Biomerica, Inc. Ms. Coste also has extensive experience in Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls, and corporate governance. Ms. Coste is a Certified Public Accountant. Ms. Coste earned her B.A. in Business Administration, Accounting, from California State University, Hayward.

Uri Geiger brings extensive entrepreneurial, management and investment know-how, having created and built many successful medical device enterprises.

Prior to founding Accelmed, Dr. Geiger founded served as CEO of Exalenz Bioscience Ltd. (TASE:EXEN), developer of an innovative breath-based technology for diagnosing liver and gastrointestinal disorders which Dr. Geiger took public in 2007 and later sold to Meridian (NASDAQ: VIVO). Prior to Exalenz, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components, sold in 2003 to MEMSCAP (EuroNext: MEMS). Dr. Geiger is also the founding partner of Dragon Variation Fund, one of Israel’s first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of capital markets and significant experience, which he put to use after returning to Israel in 1999.

Dr. Geiger was formerly an adjunct professor at the Recanati Business School at Tel Aviv University, where he lectured on private equity and venture capital. He is the author of the books: Startup Companies and Venture Capital (Tel Aviv University Press, 2001) and From Concept to Wall Street (Financial Times – Prentice Hall, 2003). He earned his doctorate from New York’s Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as a major in the Israeli Air Force.

Dr. Geiger is also involved in an extensive philanthropic activity and is the Founder & Chairman of Friends of Poriya Medical Center in the US.

Dan has over 25 years of experience in medical technology finance, investment banking, and private equity. Dan was the Israeli GM of China-based Fosun Pharma, and a principal at France-based Credit Agricole. Dan holds an MBA from ESSEC MBA, a BSc in Computer Sciences, a BA in Mathematics, and graduate studies in Biology.